Drug Profile
Research programme: CXCR3 antagonists - Pfizer
Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action CXCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myositis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Myositis in USA (Parenteral)
- 03 Nov 2017 Preclinical trials in Myositis in USA (Parenteral)
- 03 Nov 2017 Pharmacodynamics data from preclinical studies in Myositis presented at the 81st American College of Rheumatology and the 52nd Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP 2017)